CRDF News and Press, Cardiff Oncology Inc. From 04/12/22

Cardiff Oncology (NASDAQ:CRDF) shares are trading lower in the post-market Tuesday after the cancer-focused biotech announced that its chief medical officer (CMO) Katherine L. Ruffner would leave the company effective Apr. 22 to pursue a new opportunity. However, Dr. Ruffner has agreed to sup...

Cardiff Oncology Announces Departure of Chief Medical Officer PR Newswire SAN DIEGO , April 12, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies a...

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models PR Newswire - Combining onvansertib with the PARP inhibitor (PARPi...

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting PR Newswire Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castrat...

Shares of Cardiff Oncology Inc. (NASDAQ:CRDF) traded today at $25.50, eclipsing its 52-week high. This new high was reached on above average trading volume as 52.1 million shares traded hands, while the average 30-day volume is approximately 637,000 shares. In the past 52 weeks, Cardiff ...

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC PR Newswire SAN DIEGO , March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition...

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting PR Newswire SAN DIEGO , March 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop nove...

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate. The global market opportunity for colorectal cancer is expected to reach $17.8 billion by 2026. About 50% o...

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference PR Newswire SAN DIEGO , March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies ...

Cardiff Oncology press release (NASDAQ:CRDF): Q4 GAAP EPS of -$0.23 misses by $0.06. Revenue of $0.13M (+8.3% Y/Y) beats by $0.1M. CEO comment: "Looking ahead, we are eager to continue exploring synergistic combinations with onvansertib, which include DNA damaging agents, microtubule inhibito...